The effects of varenicline on stress-induced and cue-induced craving for cigarettes

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 136-142

  Ray, Lara A ^a   Lunny, Katy ^a   Bujarski, Spencer ^a   Moallem, Nathasha ^a   Krull, Jennifer L ^a   Miotto, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Craving; Cue exposure; Human laboratory; Nicotine dependence; Stress; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; GUIDED IMAGERY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STRESS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; BEHAVIOR, ADDICTIVE; BENZAZEPINES; CROSS-OVER STUDIES; CUES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGINATION; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878594375     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.015     Document Type: Article

References (57)

1. al'Absi M., Wittmers L.E., Erickson J., Hatsukami D., Crouse B. Attenuated adrenocortical and blood pressure responses to psychological stress in ad libitum and abstinent smokers. Pharmacol. Biochem. Behav. 2003, 74:401-410.
2. Allen J.P., Litten R.Z., Fertig J.B., Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol. Clin. Exp. Res. 1997, 21:613-619.
3. Ashare R.L., Tang K.Z., Mesaros A.C., Blair I.A., Leone F., Strasser A.A. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J. Psychopharmacol. 2012, 26:1383-1390.
4. Baker T.B., Brandon T.H., Chassin L. Motivational influences on cigarette smoking. Annu. Rev. Psychol. 2004, 55:463-491.
5. Biala G., Staniak N., Budzynska B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 381:361-370.
6. Brandon T.H., Drobes D.J., Unrod M., Heckman B.W., Oliver J.A., Roetzheim R.C., Karver S.B., Small B.J. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl.) 2011, 218:391-403.
7. Buchmann A.F., Laucht M., Schmid B., Wiedemann K., Mann K., Zimmermann U.S. Cigarette craving increases after a psychosocial stress test and is related to cortisol stress response but not to dependence scores in daily smokers. J. Psychopharmacol. 2010, 24:247-255.
8. Buczek Y., Le A.D., Wang A., Stewart J., Shaham Y. Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacology (Berl.) 1999, 144:183-188.
9. Childs E., de Wit H. Effects of acute psychosocial stress on cigarette craving and smoking. Nicotine Tob. Res. 2010, 12:449-453.
10. Childs E., Roche D.J., King A.C., de Wit H. Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol. Clin. Exp. Res. 2012, 36:906-914.
11. Cox L.S., Tiffany S.T., Christen A.G. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res. 2001, 3:7-16.
12. Fagerstrom K., Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr. Dis. Treat. 2008, 4:353-363.
13. Fisher R.A. On the interpretation of x(2) from contingency tables, and the calculation of P. J. Roy. Stat. Soc. 1922, 85:87-94.
14. Fucito L.M., Toll B.A., Wu R., Romano D.M., Tek E., O'Malley S.S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl.) 2011, 215:655-663.
15. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
16. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 1991, 86:1119-1127.
17. Hughes J.R. Smokers' beliefs about the inability to stop smoking. Addict. Behav. 2009, 34:1005-1009.
18. Hutchison K.E., Ray L., Sandman E., Rutter M.C., Peters A., Davidson D., Swift R. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006, 31:1310-1317.
19. Izard C.E., Libero D.Z., Putnam P., Haynes O.M. Stability of emotion experiences and their relations to traits of personality. J. Pers. Soc. Psychol. 1993, 64:847-860.
20. Jacobson A.F., Goldstein B.J., Dominguez R.A., Steinbook R.M. Interrater agreement and intraclass reliability measures of SAFTEE in psychopharmacologic clinical trials. Psychopharmacol. Bull. 1986, 22:382-388.
21. Kahler C.W., Spillane N.S., Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. Nicotine Tob. Res. 2010, 12:781-785.
22. Le Foll B., Chakraborty-Chatterjee M., Lev-Ran S., Barnes C., Pushparaj A., Gamaleddin I., Yan Y., Khaled M., Goldberg S.R. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int. J. Neuropsychopharmacol. 2011, 15:1-10.
23. LeSage M.G., Burroughs D., Dufek M., Keyler D.E., Pentel P.R. Reinstatement of nicotine self-administration in rats by presentation of nicotine-paired stimuli, but not nicotine priming. Pharmacol. Biochem. Behav. 2004, 79:507-513.
24. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol. Bull. 1986, 22:343-381.
25. Liu X., Caggiula A.R., Yee S.K., Nobuta H., Poland R.E., Pechnick R.N. Reinstatement of nicotine-seeking behavior by drug-associated stimuli after extinction in rats. Psychopharmacology (Berl.) 2006, 184:417-425.
26. McKee S.A. Developing human laboratory models of smoking lapse behavior for medication screening. Addict. Biol. 2009, 14:99-107.
27. McKee S.A., Harrison E.L., O'Malley S.S., Krishnan-Sarin S., Shi J., Tetrault J.M., Picciotto M.R., Petrakis I.L., Estevez N., Balchunas E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry 2009, 66:185-190.
28. McKee S.A., Sinha R., Weinberger A.H., Sofuoglu M., Harrison E.L., Lavery M., Wanzer J. Stress decreases the ability to resist smoking and potentiates smoking intensity and reward. J. Psychopharmacol. 2010, 25:490-502.
29. McKee S.A., Weinberger A.H., Shi J., Tetrault J., Coppola S. Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob. Res. 2012, 14:1362-1371.
30. Monti P.M., Binkoff J.A., Abrams D.B., Zwick W.R., Nirenberg T.D., Liepman M.R. Reactivity of alcoholics and nonalcoholics to drinking cues. J. Abnorm. Psychol. 1987, 96:122-126.
31. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I., Brown R.A., Gordon A., Abrams D.B., Niaura R.S., Asher M.K. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol. Clin. Exp. Res. 2001, 25:1634-1647.
32. Morgan M.J., Davies G.M., Willner P. The Questionnaire of Smoking Urges is sensitive to abstinence and exposure to smoking-related cues. Behav. Pharmacol. 1999, 10:619-626.
33. Niaura R., Abrams D., Demuth B., Pinto R., Monti P. Responses to smoking-related stimuli and early relapse to smoking. Addict. Behav. 1989, 14:419-428.
34. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., Anziano R., Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 2006, 166:1571-1577.
35. Perkins K.A. Subjective reactivity to smoking cues as a predictor of quitting success. Nicotine Tob. Res. 2012, 14:383-387.
36. Perkins K.A., Stitzer M., Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl.) 2006, 184:628-636.
37. Pomerleau C.S., Pomerleau O.F. The effects of a psychological stressor on cigarette smoking and subsequent behavioral and physiological responses. Psychophysiology 1987, 24:278-285.
38. Ray L.A., Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 2007, 64:1069-1077.
39. Rhodes J.D., Hawk L.W., Ashare R.L., Schlienz N.J., Mahoney M.C. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. Psychopharmacology (Berl) 2012, 223:131-138.
40. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., Lu Y., Mansbach R.S., Mather R.J., Rovetti C.C., Sands S.B., Schaeffer E., Schulz D.W., Tingley F.D., Williams K.E. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
41. Romberger D.J., Grant K. Alcohol consumption and smoking status: the role of smoking cessation. Biomed. Pharmacother. 2004, 58:77-83.
42. Schachter S., Silverstein B., Perlick D. 5.Psychological and pharmacological explanations of smoking under stress. J. Exp. Psychol. Gen. 1977, 106:31-40.
43. Schank J.R., Pickens C.L., Rowe K.E., Cheng K., Thorsell A., Rice K.C., Shaham Y., Heilig M. Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl.) 2011, 218:111-119.
44. Shiffman S., Waters A.J. Negative affect and smoking lapses: a prospective analysis. J Consult. Clin. Psychol. 2004, 72:192-201.
45. Singer J.D. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J. Educ. Behav. Stat. 1998, 24:323-355.
46. Sinha R. Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict. Biol. 2009, 14:84-98.
47. Sinha R., Fuse T., Aubin L.R., O'Malley S.S. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl.) 2000, 152:140-148.
48. Sinha R., Lovallo W.R., Parsons O.A. Cardiovascular differentiation of emotions. Psychosom. Med. 1992, 54:422-435.
49. Sobell M.B., Sobell L.C., Klajner F., Pavan D., Basian E. The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict. Behav. 1986, 11:149-161.
50. Toll B.A., Katulak N.A., McKee S.A. Investigating the factor structure of the Questionnaire on Smoking Urges-Brief (QSU-Brief). Addict. Behav. 2006, 31:1231-1239.
51. Toll B.A., McKee S.A., Krishnan-Sarin S., O'Malley S.S. Revisiting the factor structure of the questionnaire on smoking urges. Psychol. Assess. 2004, 16:391-395.
52. Uhart M., Wand G.S. Stress, alcohol and drug interaction: an update of human research. Addict. Biol. 2009, 14:43-64.
53. Waters A.J., Shiffman S., Sayette M.A., Paty J.A., Gwaltney C.J., Balabanis M.H. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J. Consult. Clin. Psychol. 2004, 72:1136-1143.
54. Welsch S.K., Smith S.S., Wetter D.W., Jorenby D.E., Fiore M.C., Baker T.B. Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp. Clin. Psychopharmacol. 1999, 7:354-361.
55. West R. The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD 2009, 6:277-283.
56. Yamada H., Bruijnzeel A.W. Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 2011, 60:303-311.
57. Zislis G., Desai T.V., Prado M., Shah H.P., Bruijnzeel A.W. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007, 53:958-966.